01:38 PM EDT, 04/04/2024 (MT Newswires) -- Simulations Plus ( SLP ) said Thursday that the US Food and Drug Administration has renewed its licenses to the DILIsym software platform.

Financial details weren't disclosed.

The one-year renewal will enable FDA employees to continue using the quantitative systems toxicology software, which aids in predicting and investigating drug-induced liver injuries, the company said.

Shares of Simulations Plus ( SLP ) surged more than 25% in recent trading.

Price: 48.22, Change: +9.76, Percent Change: +25.36